Received on 14 March 2021; revised on 19 April 2021; accepted on 21 April 2021
Only a few studies are available with appropriate data on the effects of non-aspirin, non-steroidal anti-inflammatory drugs (NSAIDs) use in patients with fatty liver disease. We performed a retrospective study of 1347 patients with imaging studies that showed fatty liver disease from 2016 through 2019. We then determined the change in validated indices using Fibrosis-4 (FIB4) and NAFLD fibrosis score (NFS). Patient clinical information, including NSAIDs use, was collected at baseline and then yearly. Using generalized linear models, we estimated the association between non-aspirin NSAIDs use and change in baseline indices. Non-aspirin NSAIDs use was found to be associated with significant lowering of FIB-4 score (0.596 units lower, p-value <0.0001) and NFS (0.431 units lower, p-value 0.0027) every year.
In this retrospective study of patients with fatty liver disease found on imaging, non-aspirin NSAID use was associated with lowering of fibrosis scores, suggesting that NSAID use might be associated with a lower risk for advanced fibrosis in fatty liver disease.
Ikechukwu Ronald Ogbu, Hossein Akhondi asl, Napatkamon Ayutyanont, Andre Manov and Vignan Manne. Non-aspirin NSAIDs use is associated with lowering of liver fibrosis scores in patients with fatty liver disease. World Journal of Advanced Research and Reviews, 2021, 10(1), 230-236. Article DOI: https://doi.org/10.30574/wjarr.2021.10.1.0165
All statements, opinions, and data contained in this publication are solely those of the individual author(s) and contributor(s). The journal, editors, reviewers, and publisher disclaim any responsibility or liability for the content, including accuracy, completeness, or any consequences arising from its use.